Beijing QL Biopharmaceutical Co., Ltd.

Overview

Beijing QL Biopharmaceutical (QL Biopharm) was set up in September 2018 and builds recombinant protein and peptide drugs expressed in E. coli, aimed at diabetes, obesity and NASH. Its site lists about 10 pipeline products and four technology platforms (QLFold refolding, QLLong half-life extension, QLFusion and QLOral). The FDA DMF list shows an active Type II DMF in its name for semaglutide. The company is not shown as listed on a stock exchange.

Capabilities

• Recombinant peptide/protein expression in E. coli
• Inclusion-body refolding platform
• Long-acting peptide technology
• Oral peptide formulation research
• Semaglutide drug substance

Quality signals

Sources

• qlbiopharm.com/
• fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs